Stelara Binding Assays

BioOutsource has extensive experience in the development, optimization and validation of a wide range of different types of binding assays and immunoassays and offers GCP, GLP and GMP-compliant testing services in compliance with EMA and FDA guidelines to support the biopharmaceutical industry.
Using this experience, we have created a range of off-the-shelf binding assays, including Stelara IL-12, IL-12p70, 12-p40, IL-12p80 and IL-23 binding assays, and a Stelara C1q binding assay to support process development, characterization and biosimilarity studies.

Binding assays are employed to study a number of different features of Stelara (ustekinumab) and play a vital role in the development process, by measuring the binding of Stelara to IL-12/IL-23 as well as C1q.  Our range of off-the-shelf binding methods can be used to support the development and characterization of Stelara (ustekinumab), and in the performance of extensive comparability studies:

Our binding assays can be developed using different platforms including ELISA, Electrochemiluminescence (MSD) or Surface Plasmon Resonance (SPR) and can be performed with a variety of different reporting mechanisms to provide you with the comprehensive, industry-leading comparability reports required to understand all aspects of the performance of your Stelara molecule.

BioOutsource offers cost-effective solutions to develop custom methods that are not currently in our portfolio: please contact us to find out more.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy